Journal article
Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis
A Mauguen, C Le Péchoux, MI Saunders, SE Schild, AT Turrisi, M Baumann, WT Sause, D Ball, CP Belani, JA Bonner, A Zajusz, SE Dahlberg, M Nankivell, SJ Mandrekar, R Paulus, K Behrendt, R Koch, JF Bishop, S Dische, R Arriagada Show all
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2012
Abstract
Purpose: In lung cancer, randomized trials assessing hyperfractionated or accelerated radiotherapy seem to yield conflicting results regarding the effects on overall (OS) or progression-free survival (PFS). The Meta-Analysis of Radiotherapy in Lung Cancer Collaborative Group decided to address the role of modified radiotherapy fractionation. Material and Methods: We performed an individual patient data meta-analysis in patients with nonmetastatic lung cancer, which included trials comparing modified radiotherapy with conventional radiotherapy. Results: In non-small-cell lung cancer (NSCLC; 10 trials, 2,000 patients), modified fractionation improved OS as compared with conventional schedules ..
View full abstractGrants
Funding Acknowledgements
Supported by unrestricted grants from French Programme Hospitalier de Recherche Clinique, Ligue Nationale Contre le Cancer, and sanofi-aventis (J.-P.P.). The funding sources had no role in study design, data collection, data analysis, data interpretation, or manuscript writing. Employment or Leadership Position: None Consultant or Advisory Role: None Stock Ownership: None Honoraria: None Research Funding: Jean-Pierre Pignon, sanofi-aventis Expert Testimony: None Other Remuneration: None